Introduction
Epithelial ovarian cancer (EOC) is the most common form of ovarian cancer and occurs with few or no distinct symptoms. Because of this, most women are diagnosed when disease has spread beyond the ovaries to other organs in the abdominal cavity. After initial diagnosis, patients undergo aggressive surgery to remove all visible tumors and are treated with standard combination chemotherapy consisting of a taxane and a platinum-based agent. Most patients respond well to surgery and chemotherapy, but the majority experience disease recurrence.
While additional chemotherapy may be effective for a time, recurrent disease ultimately becomes resistant to standard treatment. For these patients, there are few effective treatment options, underscoring the persistent unmet need to identify therapeutics that target pathways involved in tumor progression. Over the past two decades, significant effort has been devoted to identifying protein-targeted agents and evaluating these alone and in combination with standard cytotoxic Author Manuscript Published OnlineFirst on July 30, 2013; DOI: 10.1158/1078-0432.CCR- overexpression and/or amplification of numerous (>30) growth stimulatory genes (10) . High levels of genetic instability in these cancers may result in heterogeneity within tumors that contributes to escape from individual targeted therapeutic agents. These factors predict that monotherapy trials of agents targeting a single protein or pathway will remain unsuccessful; however, the ability to predict effective combinations of agents that will reliably inhibit EOC growth remains elusive.
Prior work from our group has shown the potential for using bioinformatics to develop target-centered signaling networks that can be used as a basis for siRNA screens designed to identify proteins regulating sensitivity to targeted therapies (11) . Observations from this dataset regarding interactions of sensitizing proteins with catalytic partners that are the targets of existing drugs were useful in predicting therapeutic combinations that were effective in preclinical in vivo studies (11) . Given the known challenges of treating EOC, and the urgent need for new treatment modalities, in the present study we have developed this initially productive strategy into a more comprehensive approach. We performed meta-analyses of five independent siRNA screens involving different combinations of cell lines and drugs to identify the most consistently sensitizing targets. We then modeled interactions among the sensitizing dataset to identify connections to therapeutic targets.
In this extended analysis, multiple proteins directly interacting with heat shock protein (HSP90) emerged as potent sensitizers of EOC cells to drug-induced cell death. HSP90 is an ATP-dependent molecular chaperone protein that affects the maturation, stability and activation mediates multiple target and pathway effects, HSP90 is an attractive therapeutic target. As an ATP-dependent chaperone, druggability of HSP90 was established in the mid-late 1990s with the natural products geldanamycin and radicicol. These agents exhibited selective toxicity for cancer cells (13) , and although too toxic for clinical use, provided the chemical framework for development of additional agents. Among these, ganetespib is a particularly promising agent that does not suffer from the toxicity issues associated with earlier-generation HSP90 inhibitors and exhibits increased potency compared to first-and other second-generation agents (14) (15) (16) (17) . In our study, we demonstrate that ganetespib is a potentially valuable agent for augmenting the activity of cytotoxic therapies commonly used in EOC, both in vitro and in vivo, and that depletion of a group of proteins physically interacting with HSP90 sensitizes EOC cells to ganetespib, suggesting directions for future combination therapies.
Research. 
Materials and Methods
Network analysis. Data for drug sensitization profiles for 638 genes encompassed in the siRNA library, corresponding to a receptor tyrosine kinase/cancer signaling network (detailed in (11)), were pooled from five independent screens of cancer cell lines. These data included sensitization of HCT116 to irinotecan or erlotinib (see Supplemental Methods and Data); A431 cells to irinotecan or erlotinib (11) ; and H1155 cells to paclitaxel (18) . Validated sensitizing siRNAs were sorted by rank for each screen, and assigned a value from 638 (most sensitizing) to 1 (least sensitizing). Comparison of the rank across screens nominated 171 siRNAs that were among the 20% strongest sensitizers in 2 or more screens. The proteins depleted by these siRNAs were imported into Cytoscape (19) and a protein-protein interaction network constructed. The network was expanded using the MiMi plugin (20) to include nearest neighbors shared by at least two proteins in the initial gene set. Analysis in Ingenuity (http://www.ingenuity.com/index.html) and DrugBank (21) was used to identify drugs targeting genes in the expanded protein set. The cumulative group of 130 drug targets was queried against the original group of 171 sensitivityregulating proteins, and topological parameters of the network calculated in Cytoscape. The degrees (the total interactions of each protein in this sub-network) of each node were used to calculate the number of connections of each of the 130 drug targets to the initial set of 171 most sensitizing genes. After HSP90 was identified as of particular interest, Ingenuity augmented by STRING (22) and manual inspection of data included in (23) , and the database of the HSP90 machine interactome (24) and http://www.picard.ch/Hsp90Int/index.php) to capture all known interactions. The prevalence of proteins from this extended dataset among the subsets of genes with varying sensitization levels was used to calculate the enrichment of HSP90 targets in each subset compared to the whole library, using hypergeometric distribution.
Research. were constructed by arraying duplicate cores from primary OVCAR-5 and A1847 tumors isolated from mice at 6 and 24 hours after treatment with vehicle or ganetespib.
Immunohistochemical staining was performed as described (30, 31) with the following antibodies at the indicated dilutions: Ki-67 (1:100), caspase-3 (1:300), PARP (1:100), STAT3
(1:400) and pSTAT3 (1:25) . Stained TMAs were scanned and analyzed using the Vectra imaging system (Perkin Elmer, Caliper Life Sciences,). Images of IHC staining were acquired on a CCD camera and Nikon Eclipse E600 microscope with NIS-Elements D3.0 software (Nikon) at identical exposure times.
Sensitization testing for siRNAs. For the set of siRNAs defined in Results, sensitization to ganetespib was performed essentially as described in detail for library screening (Supplemental Methods). Two independent siRNA duplexes independently pre-validated for each target were used in A1847 and OVCAR5 cells, using optimized reverse transfection conditions to introduce siRNAs into 3000 cells arrayed in 96 well microtiter plates, in duplicate. Plates were treated with ganetespib at a previously established IC30 concentration, or DMSO, after 24 hours, and viability assessed with CellTiter-Blue 96 hours after transfection, using an EnVision Plate Reader. We next used this data set to identify commonalities in signaling among the set of most sensitizing genes. Numerous studies of synthetic lethality have established that close physical interactions between proteins predict common functionalities that can be exploited for cell killing (36, 37) . From the starting gene set, we constructed an interaction network in Cytoscape among their encoded proteins which we augmented to include additional "nearest neighbor" interactors shared by at least two proteins in the initial group of 171 proteins. In the resulting expanded network of 1391 proteins, 130 are drug targets (Supplementary Table 2 
of the 130 drug targets and the 171 proteins regulating sensitization. From this analysis, we identified a subset of drug targets as particularly densely connected to proteins in the sensitizing network ( Figure 1B) . Within the subset of targets of the top 10 drugs, we observed that the two subunits of HSP90 (HSP90AA1 and HSP90AB1) were among the most densely connected to proteins in the sensitizing set ( Figure 1B, Supplementary Figure 2 and Supplementary Table 2) .
We also identified a statistically significant enrichment of HSP90-interacting proteins among the 20% most sensitizing siRNAs in 2 or more screens (p=0.03), and under-representation among the group of siRNAs that were never among the most sensitizing 20% (p=0.04). Moreover, many of the drug targets densely connected to the sensitizing set were themselves clients or interactors of HSP90. These included STAT3, EGFR, ERBB2 (HER2), ESR1 (estrogen receptor-α) and multiple SRC family kinases, each of which is already implicated in EOC pathogenesis ( Figure   1B ) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . elicited byHSP90 inhibitors, i.e., tanespimycin and radicicol derivatives (51), levels of HSP70 protein were increased in tumors 6 and 24 h after ganetespib treatment ( Figure 4A-B) .
Ganetespib inhibits EOC
Independent ELISA analyses confirmed the significant induction of HSP70 (2-fold at 6h and 2.4-fold at 24h) and inhibition of pSTAT3 (2.6-fold decreased at 6h) in tumors from ganetespibtreated mice (Figure 4C-D) . Immunohistochemical staining revealed no significant differences in Ki-67, caspase-3, PARP or total STAT3 levels at 6 or 24h post-dosing (not shown), but further confirmed significantly reduced levels of pSTAT3 present in tumor tissues 6h after ganetespib treatment ( Figure 4E ). These results suggested that there are differences in the timing and duration of client inhibition in vivo, and that the mechanisms of tumor inhibition likely involve multiple signaling pathways with variable kinetics. The observed single agent activity of ganetespib in EOC cells, an orthotopic xenograft model and transgenic mice predicted that this agent may be promising for the treatment of patients, but also suggested that maximum clinical advantage might be gained by combining ganetespib with other therapeutic agents in standard use or development for EOC.
In vitro assessment of ganetespib combination potential in EOC cells. Few targeted agents
are effective as monotherapy in EOC. For example, erlotinib (inhibiting EGFR) and dasatinib (inhibiting SRC family kinases) have each been evaluated in EOC patients, but neither drug showed single agent activity (7, 52) . However, given the close connection of the HSP90 clients EGFR and SRC to the sensitization network (Figure 1 ), we assessed erlotinib and dasatinib for combination with ganetespib. For this purpose, we performed Chou-Talalay analysis (53), combining each compound with ganetespib at different ratios in cultured cells. Ganetespib combined with either of these agents inhibited the growth of both A1847 and OVCAR-5 cells much more significantly than either drug administered independently (Supplementary Table 3 ). We next investigated the effect of combining ganetespib with paclitaxel and cisplatin, standard front-line cytotoxic agents used to treat EOC patients (54) (55) (56) . Notably, the combination of ganetespib was synergistic with both cisplatin and paclitaxel at all ratios tested in A1847 cells, and at some ratios in OVCAR-5 cells (Supplementary Table 3, Supplementary Figure 3) . mice with OVCAR-5 xenografts (72% versus 61% TGI); therefore, while combination therapy in A1847 xenografts resulted in 77% TGI, the difference between single agent paclitaxel and combination therapy was not significant (p=0.12) due to the potent effect of paclitaxel. Taken together, these data suggest that the combination of ganetespib with paclitaxel may be a promising clinical therapeutic strategy.
Combination
To identify potential mechanisms underlying the ganetespib-mediated sensitization to paclitaxel, we compared the effects of treatment of OVCAR-5 cells with ganetespib and paclitaxel as single agents or in combination by reverse phase protein array (RPPA) analysis. Figures 2D &4A-B) , and identified additional proteins that were significantly affected in cells treated with ganetespib alone or combined with paclitaxel ( Figure 4F and Supplementary Table 4 ). This analysis showed significant depletion of AKT/mTOR and MAPK signaling pathway proteins, kinases and transcription factors, as well as increased levels of apoptotic proteins and E-cadherin ( Figure 4F and Supplementary Table 4) . However, the analysis did not reveal proteins that were significantly more affected by the combination of ganetespib and paclitaxel compared to either drug alone.
Results of this experiment supported the immunoblot analyses (

HSP90-interacting proteins sensitize EOC cells to ganetespib.
In sum, the preceding data suggested considerable potential for supplementing standard paclitaxel regimens for EOC with ganetespib. As noted above, a number of members of the original group of HSP90-interacting proteins that led us to nominate HSP90 as a target have previously been linked to EOC pathogenesis, and in some cases been explored as drug inhibition targets in EOC. Among this group, some (including the genes PDPK1 (encoding PDK1), PRKCE (PKCε), RIPK (encoding Table 5 ). We therefore directly tested whether drug inhibition of AURKA (with alisertib), JAK2 (an upstream activator of STAT3, with ruxolitinib) or PDK1 (with GSK2334470) enhanced ganetespib activity. ChouTalalay analysis indicated significant synergy between each of these agents (alisertib, ruxolitinib and GSK2334470) and ganetespib at several different combination ratios in OVCAR-5 and A1847 cells (Table 1 and Figure 6 ). Collectively, these findings suggest the capacity of ganetespib to sensitize ovarian carcinoma cells to a broad range of cytotoxic and targeted therapeutic agents.
Discussion
Early efforts to target HSP90 with natural product antibiotics with anti-tumor activity such as geldanamycin and its analogs, including tanespimycin (17-AAG) and alvespimycin (17-DMAG), showed promising activity in clinical trials, particularly in cancers that are highly dependent on key HSP90 clients (e.g. HER2+ breast cancer) or that are sensitive to proteotoxic stress (e.g., multiple myeloma) (68, 69) . Some assessments with these first-generation agents were performed in EOC cells or tumors (70, 71) and showed anti-proliferative and pro-apoptotic effects suggesting possible clinical benefit (71) (72) (73) (74) . In spite of these encouraging data, these first generation agents suffered from limitations related to hepatic toxicity, issues related to solubility and formulation, and consequently the inability to achieve sufficient doses required for sustained client depletion (12, 75), and clinical development of these agents ceased.
The results of our meta-analysis emphasizing the importance of HSP90 in EOC were well-timed to benefit from intensive efforts focused on the development of second generation small molecule synthetic inhibitors of HSP90 with favorable biological and clinical properties.
Ganetespib (formerly STA-9090) is a highly promising anti-cancer agent (17) . In preclinical studies, ganetespib exhibited potent in vitro cytotoxicity, degradation of client proteins, superior activity to tanespimycin and in vivo anti-tumor activity in several solid tumor models including NSCLC, melanoma, prostate and gastric cancers (17, (76) (77) (78) (79) . In the clinic, ganetespib has been given to over 700 patients and is well-tolerated, with the most common side effects including fatigue, diarrhea, constipation, nausea, vomiting, anorexia and abdominal pain. 
other HSP90 inhibitors including 17-DMAG and AT13387 also emphasized the greater potency of ganetespib (14) (15) (16) (17) .
In our study, we show that ganetespib significantly reduced EOC cell viability and cell cycle progression, increased apoptosis and decreased client protein expression and stability in vitro. Ganetespib also significantly reduced tumor growth and dissemination in vivo, in the absence of any observed drug-related toxicities. Mechanistically, using both a candidate approach and RPPA-mediated screens, we found that ganetespib limited expression and/or activation of client proteins, including many linked to EOC pathogenesis, including JAK2, As with most targeted therapeutics, there is concern over intrinsic or acquired resistance.
Therefore, continued preclinical work directed at identification, analysis and validation of additional targets that sensitize EOC to ganetespib is warranted to understand mechanisms of resistance and potential ways to circumvent it. Our return to network analysis led us to investigate whether siRNAs and small molecule inhibitors of proteins from the original dataset that nominated HSP90 as a target were themselves sensitizing to ganetespib. Some of these interactors are known to be commonly activated and/or overexpressed in EOC, including AURKA and JAK2/STAT3, and we found both siRNA and small molecule inhibitors enhanced ganetespib activity (30, 41, 45, 46, (80) (81) (82) . Others, such as the SRC-related kinase FGR, the inflammation associated kinase RIPK, and the PTEN/AKT pathway kinase PDK1, have been little studied in EOC. In this study, we found that both siRNA and a small molecule inhibitor of PDK1 enhanced ganetespib action, suggesting new directions for further evaluation of drug combinations for use in EOC.
The essential strategy of combining targeted therapeutics with front-line cytotoxic agents is to target different mechanisms of action and minimize potential for overlapping toxicity. Of particular importance for clinical practice, ganetespib potently sensitized EOC cells to the effects of standard cytotoxic chemotherapy agents used for EOC patients (e.g., cisplatin and paclitaxel) in vitro, suggesting potential benefit of combining ganetespib with standard therapy in patients.
In vivo, sensitization to paclitaxel was confirmed in two independent orthotopic xenograft models. Although the underlying mechanism for this sensitization was not revealed by the RPPA analysis, we previously reported the synergistic activity of ganetespib with taxanes in NSCLC models (77) . The observed synergy may be related to disruption of cell cycle checkpoints and spindle function and will require additional studies. These results are particularly promising, as patients with recurrent and platinum refractory disease are frequently treated with paclitaxel (83) . Protein lysates were prepared and subjected immunoblot analysis with the indicated antibodies. B, Immunoblots were subjected to densitometric analysis using Image J 1.44 (NIH) to quantify each target protein levels relative to β-actin. Statistically significant differences were determined by two-way ANOVA, followed by Bonferroni post-tests (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). Detection of HSP70 (C) and pSTAT3 
